ECSP17054980A - Inhibidores selectivos de bace1 - Google Patents

Inhibidores selectivos de bace1

Info

Publication number
ECSP17054980A
ECSP17054980A ECIEPI201754980A ECPI201754980A ECSP17054980A EC SP17054980 A ECSP17054980 A EC SP17054980A EC IEPI201754980 A ECIEPI201754980 A EC IEPI201754980A EC PI201754980 A ECPI201754980 A EC PI201754980A EC SP17054980 A ECSP17054980 A EC SP17054980A
Authority
EC
Ecuador
Prior art keywords
bace1 inhibitors
selective bace1
selective
inhibitors
compound
Prior art date
Application number
ECIEPI201754980A
Other languages
English (en)
Inventor
Simon James Richards
Timothy Andrew Woods
Leonard Larry Winneroski
Jennifer Anne McMahon
Erik James Hembre
Jose Eduardo Lopez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP17054980A publication Critical patent/ECSP17054980A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula II: o una sal aceptable para uso farmacéutico.
ECIEPI201754980A 2015-02-23 2017-08-22 Inhibidores selectivos de bace1 ECSP17054980A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562119391P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
ECSP17054980A true ECSP17054980A (es) 2017-11-30

Family

ID=55442893

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201754980A ECSP17054980A (es) 2015-02-23 2017-08-22 Inhibidores selectivos de bace1

Country Status (27)

Country Link
US (1) US9522923B2 (es)
EP (1) EP3262051B1 (es)
JP (1) JP6111001B1 (es)
KR (1) KR101945139B1 (es)
CN (1) CN107257801B (es)
AR (1) AR103680A1 (es)
AU (1) AU2016223072B2 (es)
BR (1) BR112017013936A2 (es)
CA (1) CA2972098A1 (es)
CL (1) CL2017002090A1 (es)
CO (1) CO2017008382A2 (es)
CR (1) CR20170315A (es)
DO (1) DOP2017000178A (es)
EA (1) EA031546B1 (es)
EC (1) ECSP17054980A (es)
GT (1) GT201700185A (es)
IL (1) IL252969A0 (es)
MX (1) MX367940B (es)
NZ (1) NZ732940A (es)
PE (1) PE20171337A1 (es)
PH (1) PH12017501523A1 (es)
SG (1) SG11201705764SA (es)
SI (1) SI3262051T1 (es)
TN (1) TN2017000355A1 (es)
TW (1) TWI627177B (es)
WO (1) WO2016137788A1 (es)
ZA (1) ZA201704293B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9938266B2 (en) 2015-03-19 2018-04-10 Eli Lilly And Company Selective BACE1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
WO2018034977A1 (en) * 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TW201302763A (zh) 2011-05-24 2013-01-16 必治妥美雅史谷比公司 用於減少β-類澱粉產生之化合物
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI639607B (zh) * 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
SG11201705764SA (en) 2017-08-30
EP3262051A1 (en) 2018-01-03
EA201791684A1 (ru) 2017-12-29
WO2016137788A1 (en) 2016-09-01
JP6111001B1 (ja) 2017-04-05
PE20171337A1 (es) 2017-09-13
PH12017501523A1 (en) 2018-02-05
TWI627177B (zh) 2018-06-21
CO2017008382A2 (es) 2017-11-30
CL2017002090A1 (es) 2018-04-13
EP3262051B1 (en) 2019-10-02
BR112017013936A2 (pt) 2018-01-02
AU2016223072B2 (en) 2018-11-15
KR101945139B1 (ko) 2019-02-01
SI3262051T1 (sl) 2019-11-29
AU2016223072A1 (en) 2017-07-13
IL252969A0 (en) 2017-08-31
ZA201704293B (en) 2019-01-30
KR20170103971A (ko) 2017-09-13
GT201700185A (es) 2018-11-23
TW201643170A (zh) 2016-12-16
JP2017511806A (ja) 2017-04-27
MX367940B (es) 2019-09-12
CN107257801A (zh) 2017-10-17
US20160244465A1 (en) 2016-08-25
EA031546B1 (ru) 2019-01-31
CN107257801B (zh) 2019-08-13
US9522923B2 (en) 2016-12-20
TN2017000355A1 (en) 2019-01-16
CR20170315A (es) 2017-08-14
NZ732940A (en) 2019-06-28
AR103680A1 (es) 2017-05-24
MX2017010861A (es) 2017-12-11
CA2972098A1 (en) 2016-09-01
DOP2017000178A (es) 2017-09-15

Similar Documents

Publication Publication Date Title
CO2017008382A2 (es) Inhibidores selectivos de bace1
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DK3774817T3 (da) Bcl6-hæmmere
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201691421A1 (ru) Гетероарилы и их применение
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3890828T3 (da) Heteroaromatiske forbindelser som vanin-hæmmere
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CR20170050A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt